Genetic determinants for methotrexate response in juvenile idiopathic arthritis

Serena Pastore, Gabriele Stocco, Diego Favretto, Sara De Iudicibus, Andrea Taddio, Pio D'Adamo, Noelia Malusà, Riccardo Addobbati, Giuliana Decorti, Loredana Lepore, Alessandro Ventura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Juvenile idiopathic arthritis (JIAs) is the most common chronic rheumatic disease of childhood and is an important cause of disability. The folic acid analog methotrexate is the first choice disease-modifying anti-rheumatic drug in this disease, however, 35-45% of patients fail to respond. Molecular elements, such as variants in genes of pharmacological relevance, influencing response to methotrexate in JIA, would be important to individualize treatment strategies. Several studies have evaluated the effects of candidate genetic variants in the complex pathway of genes involved in methotrexate pharmacodynamics and pharmacokinetics, however, results are still contrasting and no definitive genetic marker of methotrexate response useful for the clinician to tailor therapy of children with JIA has been identified. Recently, genome-wide approaches have been applied, identifying new potential biological processes involved in methotrexate response in JIA such as TGF-beta signaling and calcium channels. If these genomic results are properly validated and integrated with innovative analyses comprising deep sequencing, epigenetics, and pharmacokinetics, they will greatly contribute to personalize therapy with methotrexate in children with JIA.

Original languageEnglish
Article number52
JournalFrontiers in Pharmacology
Volume6
Issue numberMAR
DOIs
Publication statusPublished - 2015

Fingerprint

Juvenile Arthritis
Methotrexate
Pharmacokinetics
Biological Phenomena
High-Throughput Nucleotide Sequencing
Antirheumatic Agents
Calcium Channels
Rheumatic Diseases
Genetic Markers
Folic Acid
Epigenomics
Transforming Growth Factor beta
Genes
Chronic Disease
Therapeutics
Genome
Pharmacology

Keywords

  • Gene expression profiling
  • Genome-wide association study
  • Juvenile idiopathic arthritis
  • Methotrexate
  • Pharmacogenomics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Genetic determinants for methotrexate response in juvenile idiopathic arthritis. / Pastore, Serena; Stocco, Gabriele; Favretto, Diego; De Iudicibus, Sara; Taddio, Andrea; D'Adamo, Pio; Malusà, Noelia; Addobbati, Riccardo; Decorti, Giuliana; Lepore, Loredana; Ventura, Alessandro.

In: Frontiers in Pharmacology, Vol. 6, No. MAR, 52, 2015.

Research output: Contribution to journalArticle

Pastore, Serena ; Stocco, Gabriele ; Favretto, Diego ; De Iudicibus, Sara ; Taddio, Andrea ; D'Adamo, Pio ; Malusà, Noelia ; Addobbati, Riccardo ; Decorti, Giuliana ; Lepore, Loredana ; Ventura, Alessandro. / Genetic determinants for methotrexate response in juvenile idiopathic arthritis. In: Frontiers in Pharmacology. 2015 ; Vol. 6, No. MAR.
@article{071d48d6d5f34ba8a82c2a0499cc0924,
title = "Genetic determinants for methotrexate response in juvenile idiopathic arthritis",
abstract = "Juvenile idiopathic arthritis (JIAs) is the most common chronic rheumatic disease of childhood and is an important cause of disability. The folic acid analog methotrexate is the first choice disease-modifying anti-rheumatic drug in this disease, however, 35-45{\%} of patients fail to respond. Molecular elements, such as variants in genes of pharmacological relevance, influencing response to methotrexate in JIA, would be important to individualize treatment strategies. Several studies have evaluated the effects of candidate genetic variants in the complex pathway of genes involved in methotrexate pharmacodynamics and pharmacokinetics, however, results are still contrasting and no definitive genetic marker of methotrexate response useful for the clinician to tailor therapy of children with JIA has been identified. Recently, genome-wide approaches have been applied, identifying new potential biological processes involved in methotrexate response in JIA such as TGF-beta signaling and calcium channels. If these genomic results are properly validated and integrated with innovative analyses comprising deep sequencing, epigenetics, and pharmacokinetics, they will greatly contribute to personalize therapy with methotrexate in children with JIA.",
keywords = "Gene expression profiling, Genome-wide association study, Juvenile idiopathic arthritis, Methotrexate, Pharmacogenomics",
author = "Serena Pastore and Gabriele Stocco and Diego Favretto and {De Iudicibus}, Sara and Andrea Taddio and Pio D'Adamo and Noelia Malus{\`a} and Riccardo Addobbati and Giuliana Decorti and Loredana Lepore and Alessandro Ventura",
year = "2015",
doi = "10.3389/fphar.2015.00052",
language = "English",
volume = "6",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "MAR",

}

TY - JOUR

T1 - Genetic determinants for methotrexate response in juvenile idiopathic arthritis

AU - Pastore, Serena

AU - Stocco, Gabriele

AU - Favretto, Diego

AU - De Iudicibus, Sara

AU - Taddio, Andrea

AU - D'Adamo, Pio

AU - Malusà, Noelia

AU - Addobbati, Riccardo

AU - Decorti, Giuliana

AU - Lepore, Loredana

AU - Ventura, Alessandro

PY - 2015

Y1 - 2015

N2 - Juvenile idiopathic arthritis (JIAs) is the most common chronic rheumatic disease of childhood and is an important cause of disability. The folic acid analog methotrexate is the first choice disease-modifying anti-rheumatic drug in this disease, however, 35-45% of patients fail to respond. Molecular elements, such as variants in genes of pharmacological relevance, influencing response to methotrexate in JIA, would be important to individualize treatment strategies. Several studies have evaluated the effects of candidate genetic variants in the complex pathway of genes involved in methotrexate pharmacodynamics and pharmacokinetics, however, results are still contrasting and no definitive genetic marker of methotrexate response useful for the clinician to tailor therapy of children with JIA has been identified. Recently, genome-wide approaches have been applied, identifying new potential biological processes involved in methotrexate response in JIA such as TGF-beta signaling and calcium channels. If these genomic results are properly validated and integrated with innovative analyses comprising deep sequencing, epigenetics, and pharmacokinetics, they will greatly contribute to personalize therapy with methotrexate in children with JIA.

AB - Juvenile idiopathic arthritis (JIAs) is the most common chronic rheumatic disease of childhood and is an important cause of disability. The folic acid analog methotrexate is the first choice disease-modifying anti-rheumatic drug in this disease, however, 35-45% of patients fail to respond. Molecular elements, such as variants in genes of pharmacological relevance, influencing response to methotrexate in JIA, would be important to individualize treatment strategies. Several studies have evaluated the effects of candidate genetic variants in the complex pathway of genes involved in methotrexate pharmacodynamics and pharmacokinetics, however, results are still contrasting and no definitive genetic marker of methotrexate response useful for the clinician to tailor therapy of children with JIA has been identified. Recently, genome-wide approaches have been applied, identifying new potential biological processes involved in methotrexate response in JIA such as TGF-beta signaling and calcium channels. If these genomic results are properly validated and integrated with innovative analyses comprising deep sequencing, epigenetics, and pharmacokinetics, they will greatly contribute to personalize therapy with methotrexate in children with JIA.

KW - Gene expression profiling

KW - Genome-wide association study

KW - Juvenile idiopathic arthritis

KW - Methotrexate

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84926504209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926504209&partnerID=8YFLogxK

U2 - 10.3389/fphar.2015.00052

DO - 10.3389/fphar.2015.00052

M3 - Article

AN - SCOPUS:84926504209

VL - 6

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - MAR

M1 - 52

ER -